Germany’s CureVac COVID-19 vaccine flops in clinical trial

German biopharmaceutical company CureVac’s COVID-19 mRNA vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking. “In the unprecedented context of at least 13 variants

Germany’s CureVac COVID-19 vaccine flops in clinical trial

German biopharmaceutical company CureVac’s COVID-19 mRNA vaccine candidate revealed a disappointing 47% efficacy against COVID-19 disease of any severity, and failed to meet statistical success criteria in a late-stage trial, sending stocks tanking. “In the unprecedented context of at least 13 variants